Plasma protein binding is a pharmacokinetic parameter that delineates the association between pharmaceutical agents circulating in the bloodstream and plasma proteins, particularly albumin and globulins. Upon binding to plasma proteins, a drug experiences a reduction in its bioavailability for distribution to various tissues and organs, with only the unbound fraction retaining pharmacological activity. Elevated levels of plasma protein binding are associated with prolonged drug duration, albeit concurrently heightening the potential for drug interactions. Conversely, compounds exhibiting low protein binding typically manifest a shorter half-life and expedited clearance. This phenomenon assumes a critical role in elucidating the therapeutic and toxicological profiles of drugs, alongside facilitating the anticipation of potential interactions with co-administered medications. Various determinants influence plasma protein binding, encompassing drug-specific attributes like molecular dimensions and charge, as well as patient-related factors such as age, gender, and specific medical conditions. Healthcare practitioners are obliged to factor in the nuances of plasma protein binding in medication prescription, as it profoundly shapes dosing strategies and contributes to the interindividual variability in drug responses.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia